Navigation Links
Aspartic acid in the hippocampus: A biomarker for postoperative cognitive dysfunction
Date:3/28/2014

Postoperative cognitive dysfunction is the deterioration of cognitive performance after anesthesia and surgery, and manifests as impairments in short-term memory, concentration, language comprehension, and social integration skills. Previous studies have shown that the occurrence of postoperative cognitive dysfunction is affected by many factors, including advanced age, low educational level, pre-existing cognitive impairment, alcohol abuse, and severity of coexisting illness. However, the real cause for postoperative cognitive dysfunction is still unclear. Metabolite changes have been reported in various neurodegenerative diseases, but not in postoperative cognitive dysfunction. A research team from Third Xiangya Hospital, Central South University in China performed correlation analysis between changes in hippocampal metabolites and cognitive dysfunction in aged rats, and suggested aspartic acid concentration in the hippocampus may be a biomarker for predicting the occurrence and disease progress of cognitive dysfunction. The relevant paper has been published in the Neural Regeneration Research (Vol. 9, No. 2, 2014).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert  

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
3. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
4. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
5. New biomarker for common lung cancer predicts responses to chemotherapy
6. BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research
7. Researcher uncovers potential cause, biomarker for autism and proposes study to investigate theory
8. RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
9. Imaging biomarker predicts response to rapid antidepressant
10. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
11. Spanish researchers design biomarkers for the detection of dengue and West Nile virus
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aspartic acid in the hippocampus: A biomarker for postoperative cognitive dysfunction
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: